Ecolab Inc., a company involved in water, hygiene, and infection prevention, is expanding its Purolite business with the addition of a new biologics resin manufacturing facility in Landenberg, PA. Construction plans for the new facility are underway and will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of clinical and commercial-scale therapeutics for patients worldwide.

The expansion plans for the new U.S. location include the construction of resin production facilities, cleanrooms, laboratories, and new office space. Additional land is available at the site for future expansion. The Landenberg facility will be Purolite’s fourth location in Pennsylvania. Once completed, the new facility is expected to significantly expand production capacity and add more than 150 skilled jobs in the next five years.

The Landenberg location will be Purolite’s sixth manufacturing facility globally. It will produce high-quality agarose chromatography resin for downstream monoclonal antibody and recombinant protein purification, and it will support new modality purification across cell therapy, gene therapy and mRNA.

“We are excited to announce this new facility, because of what it will mean for our customers and the many healthcare patients around the world who benefit from their innovation,” said Hayley Crowe, senior vice president and general manager, Purolite. “As Purolite continues to grow, we are committed to continued chromatography innovation and dedicated applications support, thus improving the global supply of the high-quality products to produce lifesaving and life-enhancing therapeutics.”